Cymabay Therapeutics Inc (NASDAQ:CBAY)
| 2.79 Delayed Data As of Jun 24 |  +0.20 / +7.72%Today’s Change | 1.67 Today|||52-Week Range 4.83 | -17.46% Year-to-Date |
Latest CBAY News | Press Releases
No recent news for Cymabay Therapeutics Inc.
Today’s Trading
| Previous close | 2.59 |
| Today’s open | 2.63 |
| Day’s range | 2.34 - 2.80 |
| Volume | 212,234 |
| Average volume (3 months) | 641,716 |
| Market cap | $238.8M |
Data as of 4:01pm ET, 06/24/2022
Growth & Valuation
| Earnings growth (last year) | -71.14% |
| Earnings growth (this year) | +4.72% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.80 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| DITAMCON Distributing C... | +7.17 | +4.42% |
| --FV Pharma Internatio... | 0.00 | 0.00% |
| ---- | ||
| NEUNNeuroGenesis Inc | 0.00 | 0.00% |
Data as of 3:58pm ET, 06/17/2022
Financials
| Next reporting date | August 11, 2022 |
| EPS forecast (this quarter) | -$0.29 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$90.0M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Newark, California |
Forecasts
